United Inventory Turnover vs Net Income Analysis
UTHR Stock | USD 234.06 3.87 1.63% |
United Therapeutics financial indicator trend analysis is much more than just breaking down United Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether United Therapeutics is a good investment. Please check the relationship between United Therapeutics Inventory Turnover and its Net Income accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in United Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. To learn how to invest in United Stock, please use our How to Invest in United Therapeutics guide.
Inventory Turnover vs Net Income
Inventory Turnover vs Net Income Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of United Therapeutics Inventory Turnover account and Net Income. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between United Therapeutics' Inventory Turnover and Net Income is -0.07. Overlapping area represents the amount of variation of Inventory Turnover that can explain the historical movement of Net Income in the same time period over historical financial statements of United Therapeutics, assuming nothing else is changed. The correlation between historical values of United Therapeutics' Inventory Turnover and Net Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Inventory Turnover of United Therapeutics are associated (or correlated) with its Net Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income has no effect on the direction of Inventory Turnover i.e., United Therapeutics' Inventory Turnover and Net Income go up and down completely randomly.
Correlation Coefficient | -0.07 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Inventory Turnover
A ratio showing how many times a company's inventory is sold and replaced over a period, indicating the efficiency of inventory management.Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in United Therapeutics financial statement analysis. It represents the amount of money remaining after all of United Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Most indicators from United Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into United Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in United Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. To learn how to invest in United Stock, please use our How to Invest in United Therapeutics guide.As of 04/23/2024, Enterprise Value is likely to grow to about 11.8 B, while Selling General Administrative is likely to drop slightly above 207.3 M.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 1.6B | 1.8B | 2.1B | 2.2B | Total Revenue | 1.7B | 1.9B | 2.3B | 2.4B |
United Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
United Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
United Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 3.9B | 4.6B | 5.2B | 6.0B | 7.2B | 7.5B | |
Other Current Liab | 39.6M | 319.2M | 301.6M | 339.1M | 71M | 116.3M | |
Total Current Liabilities | 463M | 323.3M | 305.4M | 343.2M | 804.4M | 844.6M | |
Total Stockholder Equity | 2.8B | 3.4B | 4.0B | 4.8B | 6.0B | 6.3B | |
Property Plant And Equipment Net | 738.5M | 731.6M | 780.9M | 861.5M | 1.0B | 1.1B | |
Net Debt | 111.6M | 61.3M | (94.8M) | (161.2M) | (507.7M) | (482.3M) | |
Retained Earnings | 3.3B | 3.8B | 4.3B | 5.0B | 6.0B | 6.3B | |
Accounts Payable | 23.1M | 9.9M | 4.1M | 3.8M | 5.6M | 10.2M | |
Cash | 738.4M | 738.7M | 894.8M | 961.2M | 1.2B | 1.3B | |
Non Current Assets Total | 2.0B | 2.4B | 2.8B | 2.7B | 3.6B | 3.8B | |
Non Currrent Assets Other | 154.6M | 169.9M | 108.2M | 114.3M | 151.8M | 91.5M | |
Cash And Short Term Investments | 2.3B | 3.0B | 3.6B | 4.2B | 3.0B | 3.1B | |
Net Receivables | 151.4M | 157.4M | 198.7M | 220.4M | 278.9M | 292.8M | |
Common Stock Shares Outstanding | 43.8M | 44.6M | 47.3M | 48.5M | 49.7M | 50.7M | |
Liabilities And Stockholders Equity | 3.9B | 4.6B | 5.2B | 6.0B | 7.2B | 7.5B | |
Non Current Liabilities Total | 670M | 896.5M | 904.8M | 904.6M | 377.8M | 269.4M | |
Other Current Assets | 133.8M | 88.3M | 100.4M | 219.2M | 166.2M | 174.5M | |
Other Stockholder Equity | (531.3M) | (430.5M) | (333.8M) | (190.8M) | (30.2M) | (28.7M) | |
Total Liab | 1.1B | 1.2B | 1.2B | 1.2B | 1.2B | 1.2B | |
Total Current Assets | 1.9B | 2.2B | 2.3B | 3.4B | 3.6B | 3.7B | |
Short Term Investments | 747.5M | 1.1B | 1.0B | 1.9B | 1.8B | 1.9B | |
Property Plant And Equipment Gross | 738.5M | 731M | 1.1B | 1.2B | 1.5B | 1.5B | |
Intangible Assets | 130.3M | 130.1M | 16.6M | 16.5M | 80.5M | 84.5M | |
Other Liab | 67M | 79.4M | 104.8M | 76.8M | 88.3M | 60.5M | |
Other Assets | 293.8M | 1.6B | 370.1M | 413.5M | 475.5M | 284.7M | |
Inventory | 93.4M | 86.5M | 93.8M | 102M | 111.8M | 55.9M | |
Property Plant Equipment | 738.5M | 731.6M | 780.9M | 861.5M | 990.7M | 1.0B | |
Net Tangible Assets | 2.6B | 3.2B | 3.9B | 4.8B | 5.5B | 5.7B | |
Retained Earnings Total Equity | 3.3B | 3.8B | 4.3B | 5.0B | 5.8B | 6.1B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether United Therapeutics is a strong investment it is important to analyze United Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact United Therapeutics' future performance. For an informed investment choice regarding United Stock, refer to the following important reports:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in United Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. To learn how to invest in United Stock, please use our How to Invest in United Therapeutics guide.Note that the United Therapeutics information on this page should be used as a complementary analysis to other United Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Complementary Tools for United Stock analysis
When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
CEOs Directory Screen CEOs from public companies around the world | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |
Is United Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of United Therapeutics. If investors know United will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about United Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.626 | Earnings Share 19.82 | Revenue Per Share 49.733 | Quarterly Revenue Growth 0.251 | Return On Assets 0.1122 |
The market value of United Therapeutics is measured differently than its book value, which is the value of United that is recorded on the company's balance sheet. Investors also form their own opinion of United Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is United Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because United Therapeutics' market value can be influenced by many factors that don't directly affect United Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between United Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if United Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, United Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.